Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/340315
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Hypothalamic JNK1-hepatic fatty acid synthase axis mediates a metabolic rewiring that prevents hepatic steatosis in male mice treated with olanzapine via intraperitoneal: Additional effects of PTP1B inhibition |
Autor: | Ferreira, Vítor; Folgueira, Cintia; García-Altares, María; Guillén Gómez, María José CSIC; Ruíz-Rosario, Mónica; DiNunzio, Giada; García-Martínez, Irma CSIC ORCID; Alén, Rosa CSIC ORCID; Bookmeyer, Christoph; Jones, John G.; Cigudosa, Juan C.; López-Larrubia, Pilar CSIC ORCID; Correig, Xavier; Davis, Roger J.; Sabio, Guadalupe CSIC ORCID; Rada, Patricia CSIC ORCID; Valverde, Ángela M. CSIC ORCID | Palabras clave: | Olanzapine Hypothalamus Inter-organ crosstalk Metabolic side-effects Liver PTP1B |
Fecha de publicación: | jul-2023 | Editor: | Elsevier | Citación: | Redox Biology 63: 102741 (2023) | Resumen: | Olanzapine (OLA), a widely used second-generation antipsychotic (SGA), causes weight gain and metabolic alterations when administered orally to patients. Recently, we demonstrated that, contrarily to the oral treatment which induces weight gain, OLA administered via intraperitoneal (i.p.) in male mice resulted in body weight loss. This protection was due to an increase in energy expenditure (EE) through a mechanism involving the modulation of hypothalamic AMPK activation by higher OLA levels reaching this brain region compared to those of the oral treatment. Since clinical studies have shown hepatic steatosis upon chronic treatment with OLA, herein we further investigated the role of the hypothalamus-liver interactome upon OLA administration in wild-type (WT) and protein tyrosine phosphatase 1B knockout (PTP1B–KO) mice, a preclinical model protected against metabolic syndrome. WT and PTP1B–KO male mice were fed an OLA-supplemented diet or treated via i.p. Mechanistically, we found that OLA i.p. treatment induces mild oxidative stress and inflammation in the hypothalamus in a JNK1-independent and dependent manner, respectively, without features of cell dead. Hypothalamic JNK activation up-regulated lipogenic gene expression in the liver though the vagus nerve. This effect concurred with an unexpected metabolic rewiring in the liver in which ATP depletion resulted in increased AMPK/ACC phosphorylation. This starvation-like signature prevented steatosis. By contrast, intrahepatic lipid accumulation was observed in WT mice treated orally with OLA; this effect being absent in PTP1B–KO mice. We also demonstrated an additional benefit of PTP1B inhibition against hypothalamic JNK activation, oxidative stress and inflammation induced by chronic OLA i.p. treatment, thereby preventing hepatic lipogenesis. The protection conferred by PTP1B deficiency against hepatic steatosis in the oral OLA treatment or against oxidative stress and neuroinflammation in the i.p. treatment strongly suggests that targeting PTP1B might be also a therapeutic strategy to prevent metabolic comorbidities in patients under OLA treatment in a personalized manner. | Versión del editor: | http://dx.doi.org/10.1016/j.redox.2023.102741 | URI: | http://hdl.handle.net/10261/340315 | DOI: | 10.1016/j.redox.2023.102741 | E-ISSN: | 2213-2317 |
Aparece en las colecciones: | (IIBM) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Hypothalamic _JNK1_Ferreira_PV_Art2023.pdf | 18,63 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
2
checked on 20-abr-2024
WEB OF SCIENCETM
Citations
2
checked on 21-feb-2024
Page view(s)
20
checked on 26-abr-2024
Download(s)
23
checked on 26-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons